Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 3Brain Neoplasms 3Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Supratentorial Neoplasms 1Stomach Neoplasms 1Seizures 1Prostatic Neoplasms 1Ovarian Neoplasms 1Ovarian Cysts 1Myofibroma 1Liver Neoplasms 1Hematologic Diseases 1Endobronchial Metastases 1Ear Neoplasms 1Cholecystitis 1Breast Neoplasms 1

Interventions

Sorafenib 42Bevacizumab 16Oxaliplatin 13Radiosurgery 10Gemcitabine 10Doxorubicin 10Capecitabine 10Leucovorin 9Hepatectomy 9Fluorouracil 9Cisplatin 9Radiofrequency Ablation 8Nivolumab 8pembrolizumab 7Drug Therapy 7Carboplatin 7Irinotecan 6Cryosurgery 6Talaporfin 5Mitomycin 5Everolimus 5Erlotinib Hydrochloride 5Electroporation 5spartalizumab 4Sunitinib 4Melphalan 4Ipilimumab 4Epirubicin 4Embolization, Therapeutic 4regorafenib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Liver Neoplasms × Remifentanil × Clear all
NCT06003218 2025-04-02

Dexmedetomidine-esketamine for Percutaneous Radiofrequency Liver Ablation

Peking University First Hospital

Phase NA Completed
88 enrolled
Gastrointestinal

Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡